Multicenter, Open-label, Randomized Study to Evaluate Inhibition of Ovulation of Two Transdermal Patch Formulations Containing 0.55 mg Ethinylestradiol and Either 1.05 or 2.1 mg Gestodene in Healthy Young Female Volunteers Over a Period of 3 Treatment Cycles
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2014
At a glance
- Drugs Ethinylestradiol/gestodene (Primary)
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Bayer
- 16 Apr 2010 Actual patient number (110) added as reported by ClinicalTrials.gov.
- 16 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jun 2009 New trial record